

2ª Convocatoria de "Acceso competitivo" a NANBIOSIS de 2025

Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS

por del Comité de Coordinación

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado, bajo las modalidades de "Acceso Abierto Competitivo" o "Acceso por Demanda". Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en "acceso por demanda". Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 2ª Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2025, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación de solicitudes y la propuesta de priorización emitida por del Comité de Acceso, acuerda:

- Conceder acceso priorizado en "modo abierto y competitivo" a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación.
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla).
- Dejar en reserva como candidatos a ser considerados como los accesos en régimen abierto y competitivo los derivados de solicitudes en naranja, las cuales cumplen con los requisitos de admisión en esta modalidad, pero que, por estar ya completa la capacidad de la unidad reservada a tal modalidad, se propone que queden en reserva para ser consideradas como acceso abierto, y obtener los beneficios de esta modalidad, en caso de que finalmente no se puedan ejecutar los accesos de las solicitudes que han quedado por delante en la lista de priorización.
- Considerar como "accesos a demanda" los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los "accesos competitivos".

Priorización de Solicitudes de Acceso a NANBIOSIS

Unidad	Solicitud	Descripción Acceso
U01 (en coordinación con U30)	4399	U1-S01. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING. U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U01 (en coordinación con U30)	4408	U1-S03: Protein purification (On-site&Remote) OUTSTANDING. U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U01	4351	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U01	4352	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U01	4411	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U01	4414	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4419	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01 (en coordinación con U30)	4427	U1-S01. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING, U1-S06: Criopreservation (On-site&Remote.)U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U01	4416	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4425	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4426	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4409	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4410	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4413	U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U01	4417	U1-S03: Protein purification (On-site&Remote) OUTSTANDING
U01	4420	U1-S04: Consultancy in protein production (On-site&Remote)
U01	4424	U1-S03: Protein purification (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U02	4326	U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING
U02	4327	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING
U02	4328	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING
U02	4329	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING
U02	4331	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING
U02	4335	U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING, U2-S07. Antibody purification (Remote) OUTSTANDING
U02	4336	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S07. Antibody purification (Remote) OUTSTANDING
U02	4412	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING
U02	4421	U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING
U02 (en coordinación con U03)	4347	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING. U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING
U02 (en coordinación con U03)	4418	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING. U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U3-S02. Post synthesis peptide modification (On-site&Remote) OUTSTANDING

U02 (en coordinación con U03)	4423	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING. U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING
U02	4415	U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U03	4369	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U3-S02. Post synthesis peptide modification (On-site&Remote) OUTSTANDING
U03	4370	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING
U03 (en coordinación con U06)	4390	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration
U03	4400	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U3-S02. Post synthesis peptide modification (On-site&Remote) OUTSTANDING
U03 (en coordinación con U02)	4347	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING. U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING
U03 (en coordinación con U02)	4418	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U3-S02. Post synthesis peptide modification (On-site&Remote) OUTSTANDING. U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING
U03 (en coordinación con U02)	4423	U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U2-S03. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U06	4385	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S02. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S06. Pulse-free microfluidic system, U6-S08. Tangential flow filtration
U06	4386	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S07. Interactions of two biomolecules with respect to binding kinetics and affinity by surface plasmon resonance (SPR), U6-S08. Tangential flow filtration
U06	4387	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S07. Interactions of two biomolecules with respect to binding kinetics and affinity by surface plasmon resonance (SPR), U6-S08. Tangential flow filtration, U6-S09. Multimode plate reader
U06	4388	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

U06 (en coordinación con U16)	4389	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S08. Tangential flow filtration. U16-S07. Evaluation of the adhesion capacities and formation of biolayers of microorganisms on materials. OUTSTANDING
U06 (en coordinación con U03)	4390	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration. U3-S01. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING
U06	4350	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	4360	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U06	4344	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U07	4384	U7-S07. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S08. Fabrication of Chromium masks (Remote) OUTSTANDING
U07	4393	U7-S01. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S07. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
U07	4405	U7-S01. Training Courses in the Use of nanotechnology equipment (Onsite)

Unidad	Solicitud	Descripción Acceso
U08	4359	U8-S06 Encapsulation or fabrication of 3D structures via 3D printing

Unidad	Solicitud	Descripción Acceso
U09	4431	U9-S02. Synthesis of Nanoparticles by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S06. Consultancy on Synthesis and Characterization of Nanoparticles (Remote)
U09	4441	U9-S06. Consultancy on Synthesis and Characterization of Nanoparticles (Remote)

Unidad	Solicitud	Descripción Acceso
U10 (en coordinación con U29)	4371	U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING
U10	4338	U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
U10	4401	U10-S03. Design & Development of solid lipid nanoparticles(SLN) (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U12	4392	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING
U12	4398	U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING

U12	4395	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING
U12	4428	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U13	4432	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (On-site) OUTSTANDING
U13	4433	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING
U13	4434	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING
U13	4435	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (On-site) OUTSTANDING
U13	4436	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (On-site) OUTSTANDING
U13	4437	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (On-site) OUTSTANDING
U13	4438	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON MicroTester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE MicroTester G2 (Onsite) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U14 (en coordinación con U21, U22 y U24)	4346	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING U24-S01. Evaluation of therapies for cardiovascular disease

Unidad	Solicitud	Descripción Acceso
U16	4368	U16-S01. XPS (Remote) OUTSTANDING, U16-S08. Electrical characterisation of surfaces through the determination of zeta potential.
U16 (en coordinación con U06)	4389	U16-S07. Evaluation of the adhesion capacities and formation of biolayers of microorganisms on materials. OUTSTANDING U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S08. Tangential flow filtration
U16	4377	U16-S01. XPS (Remote) OUTSTANDING
U16	4378	U16-S01. XPS (Remote) OUTSTANDING
U16	4379	U16-S01. XPS (Remote) OUTSTANDING
U16	4380	U16-S01. XPS (Remote) OUTSTANDING
U16	4381	U16-S01. XPS (Remote) OUTSTANDING
U16	4382	U16-S01. XPS (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U17	4342	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	4429	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U18	4403	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4404	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4407	U18-S01. In vitro Toxicology (Remote) OUTSTANDING, U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4353	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4354	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4355	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4356	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4357	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	4358	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U19 (en coordinación con U22)	4343	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote), U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site)

Unidad	Solicitud	Descripción Acceso
U20	4345	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING
U20	4330	U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S09. In vivo toxicology (Onsite&Remote) OUTSTANDING, U20-S10. In vivo ADME and biodistribution assays (Remote) OUTSTANDING
U20	4332	U20-S06. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
U20	4349	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING

U20	4443	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S02. Preclinical Experimental consultancy (Remote) OUTSTANDING, U20-S03. Detection of microbial (bacterial and mycoplasma) or endotoxin contamination, U20-S04. Hemocompatibility assays: haemolysis, platelet aggregation, plasma coagulation times and complement activation, U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others, U20-S06. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S09. In vivo toxicology (Onsite&Remote) OUTSTANDING, U20-S10. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. In vivo PK/PD assays (Remote) OUTSTANDING, U20-S12. Immunotoxicity assays (On-site&Remote) OUTSTANDING, U20-S13. X-ray imaging in vitro and in vivo (Remote) OUTSTANDING, U20-S14. Hemocompatibility: hemolysis, platelet aggregation, plasma coagulation times and complement activation, U20-S15. Cytotoxicity: proliferation, LDH, apoptosis and ROS
-----	------	---

Unidad	Solicitud	Descripción Acceso
U21 (en coordinación con U14, U22 y U24)	4346	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING U24-S01. Evaluation of therapies for cardiovascular disease. U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING
U21 (en coordinación con U22 y U24)	4383	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U22-S01. Animal Housing (Remote) OUTSTANDING, U24-S02. Medical Imaging for Minimun Invasive Surgery

Unidad	Solicitud	Descripción Acceso
U22 (en coordinación con U19)	4343	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site) U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING. U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U22 (en coordinación con U14, U21 y U24)	4346	U22-S01. Animal Housing (Remote) OUTSTANDING U24-S01. Evaluation of therapies for cardiovascular disease. U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING.
U22 (en coordinación con U21 y U24)	4383	U22-S01. Animal Housing (Remote) OUTSTANDING U24-S02. Medical Imaging for Minimun Invasive Surgery U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U24 (en coordinación con U14, U21 y U22)	4346	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING U24-S01. Evaluation of therapies for cardiovascular disease
U24 (en coordinación con U21 y U22)	4383	U24-S02. Medical Imaging for Minimun Invasive Surgery, U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
--------	-----------	--------------------

U25	4396	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4361	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4362	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4363	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4364	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4365	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4366	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
U25	4367	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U26	4341	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	4339	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	4348	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	4394	U26-S04. In vivo NMR of small animals(zebrafish,Drosophila (Remote) OUTSTANDING U26-E08. MRI equipment scanner

Unidad	Solicitud	Descripción Acceso
U27	4439	U27-S01. Remote access to HPC (On-site&Remote), U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modeling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
U27	4440	U27-S01. Remote access to HPC (On-site&Remote), U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modeling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
U27	4442	U27-S01. Remote access to HPC (On-site&Remote), U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modeling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)

Unidad	Solicitud	Descripción Acceso
U28	4340	U28-S03. Computed Tomography (CT) (Onsite&Remote)
U28	4375	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S06. Time Domain NMR (TD-NMR) (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING
U28	4376	U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S013. High-pressure freezing (Onsite&Remote) OUTSTANDING, U28-S014. Freeze substitution (Onsite&Remote) OUTSTANDING
U28	4372	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote), U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING
U28	4373	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING

U28	4374	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S021. Nuclear Molecular Imaging (PET/SPECT/CT) (Onsite&Remote)
U28	4397	U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S013. High-pressure freezing (Onsite&Remote) OUTSTANDING, U28-S014. Freeze substitution (Onsite&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U29 (en coordinación con U10)	4371	U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U30 (en coordinación con U01)	4399	U1-S01. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U30 (en coordinación con U01)	4408	U1-S03: Protein purification (On-site&Remote) OUTSTANDING U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U30	4402	U30-S08. Luminex or ELISA assay development and analysis
U30	4406	U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
U30 (en coordinación con U01)	4427	U1-S01. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S03: Protein purification (On-site&Remote) OUTSTANDING, U1-S06: Cryopreservation (On-site&Remote) U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
U30	4430	U30-S01. Sample preparation for proteomic analysis, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS, U30-S09. Data analysis of proteomics experiments
U30	4422	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments

9 de julio de 2025

Comité de Coordinación de NANBIOSIS